You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 0.0% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -17.1 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 0.0 | 0.0 |
| Price / Book value | 142.4 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | 0.52 | -6.15 | €-0.30 | -11.1 | 0.0 | n/a | n/a | 0.0% |
| 2016-12-31 | 0.95 | -10.06 | €-0.42 | -7.4 | 0.0 | n/a | n/a | 0.0% |
| 2017-12-31 | n/a | -21.06 | €-0.76 | -11.8 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | 0.02 | -20.08 | €-0.65 | -0.9 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | n/a | -13.25 | €-0.31 | -10.0 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | 0.00 | 0.00 | 0.00p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2021-12-31 | 0.00 | 0.00 | 0.00p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| Faron gets FDA tick from proposed design of next 'Traumakine' study Sharecast News | 09 Mar |
|---|---|
| Faron Pharmaceuticals acquires rights to AOC3 inhibitors Sharecast News | 02 Mar |
| Faron Pharma requests arbitration over Traumakine manufacturing deal Sharecast News | 30 Dec |
| AGM to be postponed | 03-Apr-20 14:46 |
|---|---|
| REMAP-CAP to study IFN beta-1a effect in COVID-19 | 01-Apr-20 07:05 |
| Part 1 of the MATINS Phase I/II Study Completed | 30-Mar-20 07:05 |
| Correction to Faron´s Annual Report 2019 | 26-Mar-20 10:00 |
| Faron´s Annual Report 2019 published | 25-Mar-20 07:29 |